Yes2Breathe Logo

REFERENCES

REFERENCES

  1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2019. Accessed 22 July 2020. Available from: www.ginAsthma.org
  2. Global Asthma Network. The Global Asthma Report 2018. Accessed 22 July 2020. Available from www.globalAsthmanetwork.org
  3. Asthma. National Heart, Lung and Blood Institute (NIH). Updated 21 May 2020. Accessed 22 July 2020. Available from https://www.nhlbi.nih.gov/health-topics/Asthma
  4. Pocket guide for Asthma management and prevention (for adults and children 5 years and older). Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2015. Accessed 12 January 2016. Available from: www.ginAsthma.org
  5. Take control of your Asthma. Asthma Society of Ireland. Accessed 22 July 2020. Available from https://www.Asthma.ie
  6. What is Asthma? Allergy Foundation of South Africa. Accessed 22 July 2020. Available from www.allergyfoundation.co.za
  7. Asthma Triggers and Management. American Academy of Allergy Asthma & Immunology. Accessed 29 April 2020. Available from https://www.aaaai.org
  8. Sawicki G, Haver K. Asthma Overview. Up-to-Date [Online]. Accessed 17 March 2020. Available from https://www.uptodate.com
  9. Juniper EF. Assessing health-related quality of life in Asthma. Can Respir J 1997;4(3):145-151.
  10. GINA 2024 Summary Guide for Asthma Management and Prevention For Adults, Adolescents and Children 6-11 years. Published 2024. Available from www.ginasthma.org
  11. Guidelines for Use of Nebuliser Systems in the Home Environment. Irish Thoracic Society. Accessed 02 September 2020. Available from https://irishthoracicsociety.com
  12. Getting emergency treatment through a nebuliser. Asthma UK. Accessed 29 July 2020. Available from https://www.Asthma.org.uk
  13. Breathing Exercises and Techniques for Asthma. Global Allergy & Airways Patient Platform. Accessed 29 July 2020. Available from https://gaapp.org
  14. Ding B, Small M. Disease Burden of Mild Asthma: Findings from a Cross-Sectional Real-World Survey. Adv Ther. 2017;34:1109–1127.
  15. Papaioannou AI, Kostikas K, Zervas E, et al. Control of Asthma in real life: still a valuable goal? Eur Respir Rev 2015;24:361–369.
  16. Schatz M, Sorkness CA, Li JT, et al. Asthma Control Test: Reliability, validity, and responsiveness in patients not previously followed by Asthma specialists. J Allergy Clin Immunol 2006;117:549-56.
  17. Liu AH, Zeiger R, Sorkness C, et al. Development and cross-sectional validation of the Childhood Asthma Control Test. J Allergy Clin Immunol 2007;119:817-25.
  18. Pijnenberg MW, Frey U, et al. Childhood asthma: pathogenesis and phenotypes. Eur Respir J 2022; 59:2100731.
  19. Lizzo JM, Goldin J, Cortes S. Pediatric Asthma. NCBI StatPearls [Online] 4 May 2024. Available from https://www.ncbi.nlm.nih.gov/books/NBK551631/?report=printable. Accessed 2025/04/04.
  20. Zhang D, Zheng J. The Burden of Childhood Asthma by Age Group, 1990–2019: A Systematic Analysis of Global Burden of Disease 2019 Data. Front. Pediatr. 2022;10:823399.
  21. Global Initiative for Asthma. GINA Global Strategy for Asthma Management and Prevention (2024 Update). Updated May 2024. Available from www.ginasthma.org
  22. Jenkins CR. Mild asthma: Conundrums, complexities and the need to customize care. Respirology. 2024;29:94–104.
  23. O’Byrne PM, et al. The management of mild asthma. Eur Respir J 2021; 57: 2003051.
  24. Solidoro P, Nicola S, et al. Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center. Biomedicines 2022;10:200.
  25. What is an eosinophil-associated disease? American Partnership for Eosinophilic Disorders. Available from https://apfed.org/about-ead. Accessed 2024/07/10.
  26. Eosinophilic Asthma. American Partnership for Eosinophilic Disorders. Available from https://apfed.org/about-ead/eosinophilic-asthma/ Accessed 2024/07/10.
  27. Pembrey L, Brooks C, et al. Asthma inflammatory phenotypes on four continents: most asthma is non-eosinophilic. International Journal of Epidemiology, 2023;52(2):611–623.
  28. Patel SS, Casale TB, Cardet JC. Biological therapies for eosinophilic asthma. Expert Opin Biol Ther. 2018;18(7):747–754.
  29. Oppenheimer J, Hoyte FCL, et al. Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions. Ann Allergy Asthma Immunol 2022;129:169−180
  30. Guyton S, Jackson T. Asthma Control and Medication Reliance Among Asthmatics in a General Practice Setting – A Questionnaire Based Study. Cureus 14(5): e25465.
  31. Moon Z, Kaplan A, et al. The Reliever Reliance Test: evaluating a new tool to address SABA over-reliance. Primary Care Respiratory Medicine 2024;34:36.

Important Notice:
Fraudulent WhatsApp and Facebook Group Impersonating AstraZeneca

Dear All,

Please be informed that AstraZeneca has become aware of illegitimate groups on social media platforms—including Instagram, WhatsApp, and Facebook—operating an illegal Ponzi scheme falsely claiming association with AstraZeneca. These schemes have no connection to AstraZeneca and are unlawfully using the AstraZeneca name and a fake bank account.

AstraZeneca is taking legal action to stop these activities.
We strongly advise you not to pay any fees or share any personal information with these groups, as they are entirely unaffiliated with AstraZeneca or its products.

Thank you for your attention.

AstraZeneca Pharmaceuticals (Pty) Ltd. South Africa Reg. No. 1992/005854/07
Building 2, Northdowns Office Park, 17 Georgian Crescent West, Bryanston, 2191, South Africa.
Private Bag X23, Bryanston, 2021, South Africa.
Tel: 011 797-6000. www.astrazeneca.com

Expiry date: 31 December 2025. Activity ID: ZA-6140.

Legal Notice and Terms | Cookies | Privacy Notice | Adverse Event Reporting